June 17, 2024 – WEEX, a leading cryptocurrency exchange platform, has announced a strategic partnership with K9 Finance DAO to launch projects on Shibarium, an Ethereum Layer 2 blockchain.

WEEX selects premium projects from the thousands available on the Shibarium chain for its Launchpad and will list them on WEEX, supporting the Shiba Inu (“SHIB”) community. Shiba Inu development advocates have identified WEEX as the primary platform for all new qualified projects emerging from Shibarium hackathons and developer communities worldwide.

Additionally, Andrew Weiner, VP of WEEX Global, will attend the Blockchain Futurist Conference, sponsored by Shiba Inu and K9 Finance DAO, in Toronto on August 13-14, 2024. K9 Finance DAO (“KNINE”), as the first collaborative project, will mark the beginning of this deep partnership.

Shibarium is an Ethereum Layer 2 scaling solution designed to address high gas fees and slow transaction speeds within the SHIB ecosystem. It utilizes the BONE token for gas fees, offering faster transaction speeds and lower costs. K9 Finance DAO is the official DeFi protocol of SHIB, aiming to bring decentralized finance to Shibarium and incentivize developers to build products on Shibarium through rewards. Over the next 12 months, hundreds of projects are expected to be created on Shibarium.

The WEEX Launchpad is a key use case for WEEX’s platform token, WXT, offering exclusive airdrops of popular projects to WXT holders.

WEEX, SHIB, and K9 Finance DAO are sponsors of the Blockchain Futurist Conference and ETHToronto this year. Come meet the team at their booths and cabanas and hear about the latest announcements on stage.

Claim your free ticket with the Shib Army at futuristconference.com/shibarmy

• ECGI Holdings signed an agreement in December 2023, creating Pacific Saddlery, Inc., an emerging brand targeting the luxury equestrian apparel, tack, and accessories marketplace, and continues plans to move forward in that market
• In support of growth plans, the company recently secured the first of two $125,000 convertible note financings, with the second convertible note expected to close in July
• ECGI intends to use the net proceeds from the financings to significantly enhance Pacific Saddlery’s product development, helping the brand expand its offerings and capture a significant share of the U.S. luxury equestrian market
• The U.S. luxury equestrian tack and apparel market is valued at $300 million and is expected to grow at an annual rate of 4-6%
• Besides tapping into the expected growth, ECGI’s venture into the luxury equestrian market is buoyed by attractive gross and net profit margins

December of 2023 saw ECGI Holdings (OTC: ECGI), a diversified holding company, make a strategic move toward building luxury brands. The company signed a joint venture share purchase agreement, creating Pacific Saddlery, Inc., an emerging brand targeting the luxury equestrian apparel, tack, and accessories marketplace. The agreement aligned with – and continues to align with – ECGI’s ongoing evolution, new strategic direction, and, according to CEO James Steigerwald, “commitment to building luxury brands” (https://ibn.fm/iCPAf).

A widely held belief by ECGI’s management is that the luxury equestrian marketplace is an ideal focus for investment in building a globally respected boutique brand. This belief has seen the company secure financing to facilitate further product development for Pacific Saddlery. The financing follows Pacific Saddlery’s successful mobile retail trailer launch earlier this year, and is expected to supercharge the company’s strategic growth and expansion endeavors (https://ibn.fm/nQtFh).

According to the June 4 announcement, ECGI successfully secured the first of two $125,000 convertible note financings, with the second convertible note expected to close in July under similar terms. After deducting applicable fees, ECGI will receive $100,000 in growth capital from each convertible to support major initiatives.

Mr. Steigerwald congratulated the company’s dedicated investors, who have continuously shown unwavering support, adding, “2024 is shaping up to be a transformative year for ECGI. Securing this financing allows us to significantly enhance Pacific Saddlery’s product development. We are thrilled to secure this pivotal financing, reflecting the unwavering confidence in our strategic vision. This capital infusion will propel Pacific Saddlery’s growth and enhance its product development following the success of the mobile retail trailer launch.”

U.S. Luxury Equestrian Tack and Apparel Market

ECGI notes that further product development for Pacific Saddlery will help expand the emerging brand’s offerings, capturing a significant share of the U.S. luxury equestrian tack and apparel market, a market that is uniquely profitable and consistent, with fewer pressures to “go public”. Valued at $300 million annually, the market is expected to experience steady growth at an annual growth rate of about 4-6%. This growth is expected to be driven by increasing interest in equestrian sports and leisure activities among affluent consumers, as well as innovations in product design. The strategic move also positions ECGI Holdings alongside key leaders in the equestrian market, including Hermès, Charles Ancona, and CWD Sellier.

The luxury equestrian market is segmented into two:

• The equestrian apparel segment, which comprises high-end riding gear, including breeches, jackets, boots, and helmets
• The tack and equipment segment, which includes premium saddles, bridles, and other tack, often custom-made or from renowned brands

With promises of affluence, prestige, customization, and quality, the market has spurred interest among the wealthy, affluent, and equestrian sports enthusiasts. Accordingly, major brands like Hermès, Charles Ancona, Pikeur, Animo, and Cavalleria Toscana, which focus on the apparel segment, and CWD Sellier, Hermès, Stubben, and Devoucoux, which target the tack and equipment segment, increasingly compete to deliver on these promises and, as a result, enjoy the attractive revenues and margins the industry has to offer.

Attractive Gross and Profit Margins

On average, apparel like high-end riding jackets, breeches, and boots can cost anywhere between $200 to more than $1,000 per item, while premium saddles and bridles range from $1,500 to over $10,000, depending on the level of customization and brand prestige. Usually, the premium pricing of apparel, tack, and equipment translates to high gross margins and net profit margins. For instance, luxury equestrian brands often enjoy high gross margins of 50-70%, with net profit margins varying between 10-20%.

What makes the luxury equestrian market attractive to the likes of ECGI, Pacific Saddlery, and other players is that these net profit margins are often higher than the retail market’s average. The profit margins translate to higher profitability for equestrian companies, ensuring a continuous flow of working capital. According to observers, this explains why there are no public equestrian companies – such companies are usually so profitable that they consistently have enough working capital to remain private.

As an additional testament to the veracity of this observation, Dover Saddlery, Inc., a leading specialty retailer and the largest omnichannel market of equestrian products in the U.S. at that time, was taken private in 2015. Until its delisting, the company was traded on the Nasdaq Stock Market (https://ibn.fm/D9zTc).

The attractive dynamics of the luxury equestrian market drew the interest of ECGI Holdings, explaining its decision late last year to sign the agreement that created Pacific Saddlery. Since then, the company has made strides to capture a share of the burgeoning U.S. luxury equestrian apparel and equipment market, with the latest financing supporting this resolve.

For more information, visit the company’s website at www.ECGIHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ECGI are available in the company’s newsroom at https://ibn.fm/ECGI

• Lexaria, a global innovator in drug delivery platforms, recently announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study
• The study, a randomized, crossover investigation, will evaluate a dual-action glucagon-like peptide 1 (“GLP-1”) + glucose-dependent insulintropic peptide (“GIP”)
• It will measure absorption, tolerability, pharmacokinetics, and blood sugar levels
• Lexaria is counting on its patented DehydraTECH technology for significant growth in the 2024 calendar year, and the study reflects this commitment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study. This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The manufacturing of test articles for the study is expected to be completed soon, and the approval of an Independent Review Board (“IRB”) will be required before the study commences (https://ibn.fm/OrA8d).

This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (“GIP”), specifically measuring absorption, tolerability, pharmacokinetics, and blood sugar levels. It will compare injected tirzepatide (Zepbound(R) by Eli Lilly) to a compound formulated, tirzepatide derived from Zepbound(R) and processed by Lexaria’s patented DehydraTECH technology. The objective would be to evaluate whether DehydraTECH-processed tirzepatide, when taken orally, offers any absorption into the human bloodstream and, if so, how much.

This will mark Lexaria’s first-ever work with the tirzepatide molecule while also presenting an opportunity for alternative drug delivery, particularly given that tirzepatide is currently only available in injected form.

“Many GLP-1 drugs have produced unpleasant side effects, especially when dosed through oral tablets,” noted Chris Bunka, Lexaria’s CEO. “Lexaria’s latest study in an oral capsule hopes to evidence improved tolerability while also producing measurable quantities of drug in blood. This will be Lexaria’s first-ever work with the tirzepatide molecule and, as such, any noteworthy delivery of tirzepatide through oral delivery could be a significant finding,” he added.

Lexaria is counting on its DehydraTECH technology for significant growth in the 2024 calendar year. This study reflects this commitment and affirms the leadership’s confidence in the technology. It further looks to build on the technology’s success, as demonstrated in various studies since 2016, having shown its ability to increase bio-absorption compared to standard industry formulations. Lexaria’s management is optimistic that 2024 will be the company’s best year yet, and its tirzepatide study will be a testament to that.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Israel-based SuperCom Ltd. provides a range of digital monitoring solutions to government agencies in need of technology capabilities for security purposes
• SuperCom’s PureSecurity Suite of products is particularly popular and purposeful in helping court programs to monitor suspects and offenders in rehabilitation programs as the individuals are granted supervised release from custody instead of being kept behind bars
• SuperCom recently announced it had secured a new contract with a Northern California client that further demonstrates its competitiveness and its ability to provide rehabilitative services and secure solutions
• The contract works with youth offenders in a rehabilitation program and is designed to help reduce recidivism

Secure identification and digital monitoring solutions company SuperCom (NASDAQ: SPCB) recently secured a new contract for monitoring youths transitioning through California’s justice system, demonstrating SuperCom’s competitiveness and ability to build on its reputation with existing clients.

The case management services will be provided for the California client through SuperCom’s fully owned subsidiary, Leaders in Community Alternatives (“LCA”), which provides evidence-based, community-focused services and electronic monitoring programs as a private contractor to government agencies.

“This new contract allows us to expand our reach and offer our services to a new community,” SuperCom President and CEO Ordan Trabelsi stated (https://ibn.fm/RrWeV). “With this new project, SuperCom continues to strengthen its position as a leader in providing rehabilitative services and secure solutions.”

The California contract reflects a trend worldwide for court and law enforcement advocates to seek privately contracted rehabilitative service and electronic monitoring (“EM”) solutions providers that allow teen suspects to enjoy a measure of freedom and community interaction while under court supervision, with the hope of reducing recidivism.

SuperCom’s technology (https://ibn.fm/LoAHT) has the capacity to placate critics of such measures who fear EM programs will stigmatize children and “expand the walls of youth prisons into children’s homes and communities.”

The company’s monitors are easily concealable to reduce concerns about stigmatizing their wearers while providing effective, cost-efficient monitoring with artificial intelligence (“AI”) enhanced data analysis and predictive modeling that meets law enforcement needs for protecting the community.

The new contract also builds on SuperCom’s global reach that thus far includes clients mainly in Europe and the United States.

“This program underscores our commitment to providing comprehensive support services that make a tangible difference in the lives of young individuals. By focusing on evidence-based case management, we are addressing some of the most pressing needs of youth in transition,” Organ added.

Market analysts predict the court-administered EM sector may reach $2.3 billion in global revenues by 2029 at a 9.5 percent CAGR (https://ibn.fm/nMcHq), reflecting the opportunities available to SuperCom and its PureSecurity Suite of products.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Hudbay Minerals paying $439 million in June 2023 for 75% stake in Copper Mountain Mine exemplifies potential for Canada’s emerging “Copper Highway”
• Torr Metals recently expanded its land package at its Kolos Copper-Gold project in the heart of the region by 75% to 240-square kilometers
• Historical rock grab samples at Kolos have yielded high grades, such as 4.24 g/t Au, 0.52% Cu, and 11.3 g/t Ag, yields that company hopes will be further validated soon with the arrival of a spate of samples and survey data

Canada’s mining industry is booming and gaining steam, fueled by an increased focus on copper exploration and development. It’s no secret that metals like copper are in tremendous demand owing to sustainability goals worldwide. British Columbia’s south-central region stands out as a crown jewel in this exciting trend, as a highly attractive and the most productive copper mining district in all of Canada.

Several established copper mines have already cemented the south-central region’s reputation as a copper powerhouse. Hudbay Minerals Copper Mountain copper-gold open-pit mine, for instance, has been churning out valuable resources since August 2011, with a milling capacity of 45,000 tones per day. In June 2023, Hudbay paid an estimated $439 million to buy Copper Mountain Mining Corp. to gain a 75% interest in the mine. This strategic move solidified Hudbay’s position as the third largest copper producer in Canada, highlighting the immense potential of the region.

But the story doesn’t end there. The future promises even more. Exploration activity is booming, with estimates suggesting over $83.7 million dedicated to exploration expenditures and over 110,000 meters of drilling planned, according to the BC Geological Survey.

Torr Metals (TSX.V: TMET) and its Kolos copper-gold project are a prime example of the new wave of exploration driving this economic security of the nation and North America. Located in the heart of this prolific copper/gold belt, the Kolos project is underlain by Nicola Group (Late Triassic) volcanic and sedimentary rocks, which are intruded by Late Triassic granodiorite to quartz monzonite rocks – a geological sweet spot for copper porphyry deposits in the region. The company’s recent 75% expansion of the project to 240-square kilometers demonstrates their unwavering commitment to unlocking the region’s major copper porphyry discovery potential.

Historical rock grab samples at Kolos have yielded high-grades, such as 4.24 g/t Au, 0.52% Cu, and 11.3 g/t Ag within a newly established seven-kilometer trend of untested >200 ppm Cu soil anomalies. To that end, the company and its investors are eagerly awaiting pending assay results from 2023 rock (46) samples as well as phase 1 of 2024 surface sampling that will offer further insights into planning expanded operations in 2024.

While Kolos is an exciting opportunity, it is only a piece of the Torr portfolio. Torr holds 100% ownership in over 1,000-square kilometers of strategically located gold and copper projects across Canada, positioning the company for potentially significant returns in multiple favorable regions. These include the Filion Au Project (261 km²) in northern Ontario and the Latham Cu-Au Project (689 km²) in BC’s Golden Triangle.

The activity of Torr and others in south-central BC is a beacon for investors looking to capitalize on the rush. This combined effort positions the south-central region as a true “Copper Highway” – a corridor of mining activity that will not only benefit mining companies but also generate significant economic prosperity for local communities and the nation.

Copper Mountain is just one example of lengthy mine life potential that Torr is aiming to replicate across its expansive property. Within 30 kilometers of Kolos are two additional established copper porphyry mines, including Teck Resources’ Highland Valley Copper Mine and New Gold’s New Afton Mine that are seeing efforts to extend their life; demonstrating the long-term commitment to this copper and gold-rich area.

With its potential and ongoing exploration activity, the region is poised to remain a leading light in Canada’s copper boom. Companies like Torr Metals are at the forefront of this development, and their success will be a key driver of future deal flow in the Canadian mining industry. With the recent expansion at Kolos, a spate of survey data anticipated, and more exploration on tap, this story is just beginning to be told.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

• Rob McEwen recently spoke at the NYC SME’s 9th Annual Current Trends in Mining Finance Conference, emphasizing the importance of mining in sustaining modern civilization
• McEwen pointed out that those opposed to mining often cite environmental concerns, but they fail to recognize the unintended consequences of shutting down industries that are fundamental to modern living
• McEwen offered 10 strategic recommendations to make mining relevant to the public and address industry challenges

Rob McEwen, CEO of McEwen Mining (NYSE: MUX) (TSX: MUX), an asset rich diversified gold and silver producer in the Americas, recently spoke at the NYC SME’s 9th Annual Current Trends in Mining Finance Conference, where he emphasized the crucial importance of the mining industry to modern civilization and outlined a strategic approach to improving its public perception. His address highlighted the stark reality of a world without mining and its interconnected industries, particularly oil and gas.

McEwen began by challenging the audience to imagine a world devoid of mining, pointing out that while such a scenario might seem amusing momentarily, it would quickly lead to the collapse of modern civilization. The necessity of mining for the continuation of contemporary life is undeniable, yet, as McEwen pointed out, a significant portion of the population remains blissfully unaware of this fact. This ignorance is compounded by societal conditioning that teaches a deep-seated hatred for the industry.

The opposition to mining, often rooted in environmental concerns, fails to recognize the unintended consequences of shutting down an industry fundamental to modern life. McEwen also stressed that removing hydrocarbons from our lives would lead to a dystopian future, a collapse far more chaotic and desperate than most could imagine.

The central theme of McEwen’s speech was the urgent need to alter the public’s negative perception of the mining industry. This change, he argued, could be achieved by showcasing the industry’s essential contributions to daily life and modern technologies, particularly those aimed at combating climate change. By highlighting the vast range of products derived from minerals and the environmental stewardship efforts within the industry, McEwen believes the public can be swayed to view mining more favorably.

McEwen acknowledged the effectiveness of the opposition’s campaign, particularly among the youth, who are taught from a young age to view mining as destructive. To counteract this narrative, he proposed a proactive approach: educating educators, utilizing modern media tools, and presenting vivid, positive examples of the industry’s impact on local communities and the environment.

To make mining relevant to the public and address the industry’s challenges, McEwen offered ten strategic recommendations:

1. Surprise the Majority: Educate the public about their everyday reliance on mining, especially in technologies that combat climate change.
2. Broaden Our Reach & Turn up the Volume: Engage suppliers and allied industries in promoting the benefits of mining.
3. Showcase Environmental Protection: Highlight reclamation successes and ongoing environmental protection efforts.
4. Share Community Stories: Emphasize the positive impact of mining on local businesses, services, and job opportunities.
5. Educate Influencers: Show the critical connection between mining, modern life, and climate change mitigation, while promoting career opportunities.
6. Improve Remote Site Conditions: Enhance accommodations and benefits to attract top talent.
7. Highlight Compensation & Career Paths: Showcase the high pay and rapid career advancement opportunities in mining.
8. Join Forces with Oil & Gas: Collaborate on marketing efforts to improve public perception.
9. Pressure Governments: Lobby for political support and recognition of mining’s contribution to modern life.
10. Address Workforce Shrinkage: Embrace automation and AI to mitigate the shrinking workforce.

McEwen drew inspiration from successful industry transformations, such as Uber’s disruption of the taxi industry and Tesla’s revolution in electric vehicles. These examples demonstrate the power of addressing public complaints and delivering a superior customer experience. By adopting a similar approach, the mining industry can reshape its image and gain broader acceptance.

Working together to change opinions and highlight the industry’s essential contributions, McEwen believes the mining sector can prevent a world that is “naked, homeless, and hungry.” It is time for the industry to step onto the global stage with a message of relevance, responsibility, and opportunity, he explained.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

• In the chemical manufacturing industry, innovative uses of mass spectrometry are a game-changer by ensuring quality control, increased yields, and increased profits
• Astrotech subsidiary, Pro-Control Inc., has positioned its product line between the need for the chemical manufacturers to offset lower prices with efficiency gains that could offset potential losses
• The Pro-Control Maximum Value Processing(TM) can perform in-situ process tests every 5 minutes greatly increasing efficiency across a wide range of chemical manufacturing processes

Mass spectrometry (“MS”) is becoming a transformative analytical technique that has revolutionized how materials are tested and processed in various industries, such as petrochemical. The supreme accuracy of MS in analyzing the molecular structure, purity, and potency of a substance has made it an indispensable part of several key sectors. In manufacturing settings, MS is a game-changer, as it is able to enhance the production processes with higher purity and yields. A key benefit is the ability to make these determinations directly in the production process making near-real-time adjustments, versus the delays traditionally incurred by sending the samples to the lab.

The global mass spectrometry market was valued at $5.4 billion in 2023 and is expected to grow to $7.8 billion by 2028, expanding at a CAGR of 7.5% (https://ibn.fm/UvTfe). The technology’s capability to provide rapid, accurate, and detailed analysis makes it a growing preference for industries looking to enhance productivity and ensure product quality.

Astrotech (NASDAQ: ASTC), an instrumentation company that designs, manufactures, and commercializes mass spectrometry solutions, is expanding access to this technology through Pro-Control and its other vertically focused subsidiaries.

Pro-Control, a true innovator, harnesses the power of advanced mass spectrometry in its Pro-Control-1000(TM) rugged factory-floor instrument that allows production managers access to real-time testing results providing actionable information where previously it would have taken hours or days. This immediate, on-site, access to the highly accurate MS data provided by the Pro-Control-1000(TM) increases potency, purity and ending weight yields.

Role in Petrochemical Processing

Mass spectrometry is an invaluable analytical technique in the petrochemical industry, allowing for the identification and quantification of individual chemical components present in complex petroleum samples. This data is crucial for optimizing production processes, monitoring emissions, and ensuring the quality of finished products.

Application in Pharmaceutical Manufacturing

In pharmaceuticals, the precision of mass spectrometry is critical. It helps confirm drug molecules’ molecular structure and purity, which is essential for ensuring safety and efficacy. MS also plays a crucial role in identifying impurities or contaminants that might compromise the drug’s quality. Furthermore, it quantifies the levels of drugs in formulations, which is vital for accurate dosing. Another significant application is in characterizing protein-based biopharmaceuticals, such as antibodies, where MS provides essential information on molecular weight and structure.

Utility in the Food and Beverage Industry

The food and beverage sector also greatly benefits from mass spectrometry. MS techniques are used to test for pesticide residues, allergens, and other contaminants in food products. This helps ensure compliance with safety regulations and ensures consumer trust. Additionally, mass spectrometry assists in verifying the contents of nutritional labels—such as vitamins and proteins—enhancing label accuracy and transparency. It also detects food adulteration and identifies sources of spoilage or contamination, crucial for maintaining food quality.

Impact on Polymer and Materials Manufacturing

Mass spectrometry provides detailed insights into polymers’ molecular weights and compositions, which are vital for developing new materials with desired properties and performance. MS analyses additives and fillers in plastics and composites, ensuring products meet stringent quality specifications. It is also used to characterize surface coatings and thin films, critical for applications in industries like automotive and aerospace.

Role in Environmental Testing

Environmental testing is another critical application of mass spectrometry, where it identifies pollutants and toxins in air, water, and soil samples. This capability is essential for monitoring environmental health and compliance with regulations. Additionally, mass spectrometry measures isotopic ratios, aiding in geochemical and environmental tracing, which helps in understanding environmental changes and pollutant sources.

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

• INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease
• The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model
• Recent preclinical data for INM-901 displayed positive pharmacological effects for treating Alzheimer’s disease
• INM posted a business update for Q3-2024 reporting a closing cash position of US$7.9 million and revenue growth for subsidiary BayMedica, a supplier of rare cannabinoids as ingredients

InMed Pharmaceuticals (NASDAQ: INM), a is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Degeneration (“AMD”) and its INM-901 small molecule drug candidate targeting Alzheimer’s disease (“AD”).

Recent preclinical data for INM-089 demonstrated significant functional and pathological improvements in an AMD disease model, indicating promising neuroprotective effects in the back of the eye. “We are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from INM-089 in the AMD model,”  said Dr. Eric Hsu, SVP of Preclinical Research and Development at INM (https://ibn.fm/taLK6).

“While a few treatment options are currently available, their efficacy is limited and may be associated with several undesirable side effects. We see an opportunity for INM-089 to slow the progression and to fill a significant gap in the treatment of this chronic disease.”

INM-901 is currently being investigated for its potential in treating Alzheimer’s disease. Recent preclinical data showcased its positive pharmacological effects, demonstrating reduced neuroinflammation and improved neuronal function, among other promising outcomes. The small molecule drug, acting as a preferential signaling ligand for CB1/CB2, delivers improved retinal pigment epithelium integrity, neuroprotection, and photoreceptor improvement in an in vivo preclinical disease model.

“The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD,” said Dr. Eric Hsu (https://ibn.fm/qUx1Z). “There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis.”

InMed additionally provided a business update for the third quarter of fiscal year 2024, highlighting progress in its pharmaceutical pipeline and commercial business growth (https://ibn.fm/LkynB). Highlights included a closing cash position of US$7.9 million and strong revenue growth for its subsidiary BayMedica, a B2B supplier of rare cannabinoids as ingredients to the health and wellness sector.

InMed Pharmaceuticals Inc. stands at the forefront of cannabinoid research, pioneering advancements in the development of proprietary small molecule drug candidates targeting different specific receptors. With an experienced management team leveraging expertise in pharmaceutical research, manufacturing, and commercialization, the company is advancing novel therapies to address unmet medical needs across a spectrum of diseases and disorders.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

The upcoming 4th Chief Patient Officer Summit, hosted by Dynamic Global Events, will convene on July 15-16, 2024, in Boston, MA. Professionals in Patient Affairs, Clinical Trials, Patient Communications, Patient Advocacy, and related industry areas are invited to attend at the Hilton Boston Back Bay.

The summit, which will include panel presentations, two concurrent workshops, and networking opportunities, will gather top leaders from the healthcare industry to focus on patient engagement and advocacy.

As the most extensive forum to focus on the role of the Chief Patient Officer, 44 distinguished speakers will share their insight to explore solutions to the largest challenges.

The summit will feature distinguished speakers including:

• Dr. Beth Frates, President of the American College of Lifestyle Medicine
• Ifeyinwa Osunkwo, MD, Chief Patient Officer at Novo Nordisk Rare Disease
• Tricia Mullins, Executive Director, Global Head, Early Patient Engagement & Professional Societies at Beigene
• Wendy Erler, Vice President, Global Head, Patient Experience, Patient Advocacy & Patient Caregiver Insights at AstraZeneca

View the agenda to meet the full speaking faculty.

Attendees will explore key topics like regulatory strategies, health equity, and patient-centric innovations, fostering a collaborative environment to enhance patient care across the industry.

For conference and registration details, visit www.dgevents.com/event/chief-patient-officer-summit/

*Use discount code IBN2024 to save 15% off*

• Bloomberg analyst projects 2024 EV sales in the U.S. at nearly 2 million units, making up 13% of new-car purchases
• Mullen subsidiary inks first commercial dealership agreement with LaFontaine Automotive Group
• Bollinger Motors expects to start delivering the Bollinger B4 later this year

While some headlines in the past few months make it seem like the electric vehicle market is in trouble, a recent “Car and Driver” article forecasts that EV sales are just getting started. Mullen Automotive (NASDAQ: MULN), an emerging EV manufacturer, appears to support that projection, with the recent announcement that its subsidiary, Bollinger Motors, has entered a distribution deal with LaFontaine Automotive Group to become its first commercial dealership (https://ibn.fm/G0kGO).

In related news, Car and Driver recently debunked the idea that EV sales are slowing. “Over the past few months, multiple media outlets have suggested that U.S. sales of electric vehicles are losing steam, or have stalled out, or look grim for 2024, or that makers, dealers and buyers are dawdling.” For example, the article noted, Hertz has been shrinking its EV inventory. In addition, “Some point to carmakers delaying or reducing previous EV investments; others suggest the U.S. (and other countries) won’t hit their goals for EV sales percentages in 2030 or 2035. A few even question whether the EV transition will happen at all.

“There’s just one little problem,” the article continued. “Last year, U.S. sales of EVs were the highest ever, both in sheer numbers and as a percentage of the overall new-car market. Global sales: ditto. The EV Sales Tracker from EVadoption estimates nearly 1.2 million battery-electric vehicles and another 190,000 plug-in hybrids were sold in 2023, totaling 1.36 million vehicles. That’s 8.8% of the total of 15.5 million, per Wards Intelligence — and it represents EVs’ highest-ever share of new-car sales.”

Car and Driver also stated that this year is expected to set another new record for volume of EVs sold and their share of the total market, noting that Colin McKerracher of Bloomberg projects 2024 EV sales in the U.S. at just under 1.9 million units, making up 13% of new-car purchases. “This year should see fewer of the supply constraints that hobbled availability over the last four years,” the article concludes. “Depending on a host of factors, some analysts suggest overall vehicle sales could be 1 million vehicles or more higher than last year.”

That’s great news for both Mullen and Bollinger, which will produce the Bollinger B4 Chassis Cab, an all-new, all-electric class 4 commercial truck designed from the ground up. The company expects to start delivering the Bollinger B4 in the second half of 2024 and will deliver a number of these trucks to its new dealership partner: LaFontaine Automotive Group.

“We are thrilled to work with LaFontaine right here in Michigan where we designed, and will build, the B4,” said Robert Bollinger, founder and CEO of Bollinger Motors. “LaFontaine shares our commitment to quality and customer service.” Bollinger will bring LaFontaine’s portfolio to 54 retail franchises and 39 retail locations, with additional announcements planned later this year.

“Our strategically developed plan to offer sales and service nationwide is being kicked off with LaFontaine,” said Jim Connelly, chief revenue officer at Bollinger Motors. “Additional dealer partners will be announced soon, showing our commitment to fleets in all 50 states.”

Mullen Automotive (NASDAQ: MULN) is a Southern California–based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States–based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. Recently CARB issued HVIP approval on the Mullen THREE, Class 3 EV truck, providing a cash voucher of up to $45,000 at the time of vehicle purchase. The company has also recently expanded its commercial dealer network with the addition of Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, and Range Truck Group, providing sales and service coverage in key Midwest, West Coast, and Pacific Northwest markets. The company also recently announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles.

For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN